Iron Infusion and IV Iron Therapy: Mechanism, Evidence and Why This Route Earns Its Claim

In short: iron is the one molecule in this series where the intravenous route wins the arithmetic outright. A licensed course delivers 1,000 to 1,500 mg of elemental iron in one or two infusions — 1,000 mg of ferric carboxymaltose goes in over a minimum of fifteen minutes — while an oral dose yields on the order of 10 mg absorbed and then suppresses absorption of the next dose for about a day. That is why ferric carboxymaltose and ferric derisomaltose are prescription medicines and not drip-bar extras. The licence, however, is narrow. Ferinject's summary of product characteristics authorises it only "when oral iron preparations are ineffective, cannot be used, or there is clinical need for rapid iron delivery", and states that the diagnosis "must be based on laboratory tests". Two regulators tightened it further within three days of each other: on 1 September 2026 the FDA added a boxed warning to Injectafer for severe, prolonged hypophosphataemia, and on 3 September 2026 the EMA opened an Article 31 review of every parenteral iron product over hypophosphataemia and hypophosphataemic osteomalacia. That risk is formulation-specific, not class-wide — in two randomised trials, hypophosphataemia occurred in 75.0% and 73.7% of ferric carboxymaltose recipients against 7.9% and 8.1% with ferric derisomaltose, at equivalent haemoglobin response. And iron carries an upper bound no other nutrient here has: genetic evidence links higher systemic iron status to reduced healthspan and lifespan. The route earns its claim inside a diagnosis, and not one milligram beyond it.

The deficit is measured in milligrams, and the gut rations them

Start with the size of the problem, because that is where every previous article in this series found the intravenous argument collapsing.

Iron deficiency is not corrected in micrograms. The licensed course sizes are the clinical answer to how large the gap usually is: the US label for ferric carboxymaltose specifies 750 mg in two doses at least seven days apart, a total of 1,500 mg per course, or a single 15 mg/kg dose up to 1,000 mg; ferric derisomaltose is given as 1,000 mg in a single infusion over at least twenty minutes for adults weighing 50 kg or more. Ferinject's summary of product characteristics sets a maximum single dose of 1,000 mg of iron, delivered over a minimum of fifteen minutes, with no more than 1,000 mg in a week.

Now the oral side. In iron-depleted women given 60 mg of elemental iron daily for fourteen days, cumulative fractional absorption was 16.3% and cumulative total absorption 131.0 mg — around 9 mg of iron actually crossing the gut per dose. Replacing 1,000 mg at that rate takes something over three months of uninterrupted, tolerated, correctly timed dosing, and oral iron is frequently none of those things.

This is the comparison that failed for every other molecule here. Oral biotin is essentially completely absorbed, so the needle added nothing. A bag of amino acids cannot contain intact collagen whatever the route. High-dose vitamin C needed the intravenous route only to reach pharmacological plasma concentrations, which is a different argument from a delivery deficit. Iron is the first case where the gut is the genuine bottleneck, and the bottleneck has a name.

Hepcidin: why daily tablets defeat themselves

Hepcidin is a liver peptide that binds ferroportin, the only known cellular iron exporter, and degrades it. When hepcidin is high, iron absorbed into the enterocyte stays there and is shed with the cell. An oral iron dose raises serum hepcidin, and the rise lasts roughly twenty-four hours.

Two open-label randomised trials published in Lancet Haematology in 2017 tested what that means for a dosing schedule. Iron-depleted women received 60 mg of iron daily for fourteen days or on alternate days for twenty-eight days, with absorption measured by stable isotopes. Cumulative fractional absorption was 21.8% on alternate days against 16.3% on consecutive days, and cumulative total absorption 175.3 mg against 131.0 mg. A parallel comparison found that twice-daily split dosing raised hepcidin more than a single morning dose.

A crossover study in iron-deficient anaemic women, published in Haematologica in 2020, reproduced the mechanism directly. Fractional absorption on day 3 of consecutive dosing was significantly lower than on days 2 and 5 of alternate-day dosing, serum hepcidin rose sharply twenty-four hours after a dose and returned towards baseline by forty-eight, and alternate-day dosing at 200 mg delivered approximately twice the total iron of consecutive-day dosing at 100 mg.

The practical conclusion is counterintuitive and cheap: one tablet every other day can deliver more iron than two tablets a day, with fewer gastrointestinal effects. British Society of Gastroenterology guidance already allows for it, recommending a reduced dose of one tablet every other day where daily dosing is not tolerated, before parenteral iron is considered.

What does not help is the oldest piece of advice in the field. A randomised equivalence trial in JAMA Network Open in 2020 gave 440 adults with iron-deficiency anaemia oral iron with or without 200 mg of vitamin C every eight hours. Haemoglobin rose 2.00 g/dL with vitamin C and 1.84 g/dL without it at two weeks, meeting the equivalence criterion. Ascorbate does enhance non-haem iron absorption from a meal; it does not measurably improve the treatment of established deficiency with a supplement.

What the licence actually authorises

Because intravenous iron works, it is easy to assume it is simply the better option. The marketing authorisation says otherwise, in unusually plain language.

Ferinject is indicated, per its summary of product characteristics, "for the treatment of iron deficiency when oral iron preparations are ineffective, cannot be used, or there is clinical need for rapid iron delivery", and "the diagnosis of iron deficiency must be based on laboratory tests". The US labels are built the same way: Injectafer, revised in August 2026, is indicated for iron-deficiency anaemia in patients with intolerance or an unsatisfactory response to oral iron, in adults with non-dialysis-dependent chronic kidney disease, and for iron deficiency in adults with NYHA class II or III heart failure to improve exercise capacity. Monoferric is indicated for iron-deficiency anaemia in adults intolerant of or unresponsive to oral iron, and in non-dialysis-dependent chronic kidney disease.

Three things follow. The route is second-line by licence, not by preference. An infusion given without laboratory confirmation sits outside the authorisation regardless of how the patient feels. Nothing about the regional market changes that: the two documents deciding whether a given infusion falls inside the licence are the approved product information and the patient’s iron panel. And "iron for energy" as a standing wellness offer describes a use that no regulator has assessed — the same structural position the series described for injectable vitamin D, where the route existed but the authorisation did not cover the use being sold.

September 2026: two regulators moved on phosphate

Within three days last month, the two largest medicines regulators in the world acted on the same adverse effect.

On 1 September 2026 the FDA issued a drug safety communication adding a boxed warning to ferric carboxymaltose. The warning states that Injectafer "can cause severe, prolonged hypophosphatemia associated with serious outcomes, including hospitalization, osteomalacia and fractures requiring clinical intervention", and notes that it can occur in patients with normal baseline phosphate and no apparent risk factors. The agency observed that serum phosphate testing occurs in fewer than 20% of ferric carboxymaltose administration episodes, and that symptomatic cases have continued to be reported despite labelling updates in 2020 and 2023. The revised label requires checking serum phosphate before a repeat course in at-risk patients and in anyone receiving a repeat course within three months, and correcting pre-existing hypophosphataemia first.

On 3 September 2026 the European Medicines Agency started an Article 31 referral at the request of the Austrian agency, covering ferric carboxymaltose, ferric derisomaltose, iron dextran, ferric gluconate, ferric hydroxide polymaltose complex and iron sucrose. The EMA notes that hypophosphataemia is listed as a common side effect, affecting up to one in ten people, that the frequency of hypophosphataemic osteomalacia is unknown because the data do not allow an estimate, that symptoms such as tiredness, muscle pain and bone pain overlap with those of iron deficiency itself, and that bone changes may not always be visible on X-ray. The review is open; no conclusion has been published.

The mechanism explains why this is not a class effect. Ferric carboxymaltose raises intact FGF23, which drives renal phosphate wasting, reduced calcitriol and secondary hyperparathyroidism. Two identically designed randomised trials published in JAMA in February 2020 — 123 and 122 patients — measured the consequence directly: incident hypophosphataemia, defined as serum phosphate below 2.0 mg/dL, occurred in 75.0% and 73.7% of ferric carboxymaltose recipients against 7.9% and 8.1% of those given iron isomaltoside, now ferric derisomaltose, with adjusted differences of −67.0% and −65.8% and equivalent haemoglobin response. A 2025 systematic review in the American Journal of Hematology pooled the picture: 47% against 4% across trials, nadir around day 14, and moderate or severe hypophosphataemia persisting in 35% of affected patients at 61 to 90 days.

Two qualifications matter and belong in the same paragraph as the numbers. The JAMA authors stated explicitly that further research was needed to determine the clinical importance of the difference, and most episodes are asymptomatic and self-limiting. The MHRA had already flagged the risk in a Drug Safety Update of 16 November 2020, listing vitamin D deficiency, calcium and phosphate malabsorption, secondary hyperparathyroidism, inflammatory bowel disease and osteoporosis as risk factors. What changed in September 2026 is not the science but the regulatory weight attached to it.

Reactions, and what the 2013 referral settled

The other safety question is older and better resolved.

The EMA's 2013 Article 31 review of intravenous iron reached two conclusions that still govern practice. A small test dose is not a reliable way to predict the response to a full dose and is therefore no longer recommended; caution is required with every dose, even in patients who have tolerated previous administrations. And intravenous iron should be given only where staff trained to evaluate and manage anaphylactic reactions are immediately available in an environment with full resuscitation facilities, with observation for at least thirty minutes after each administration. Ferinject's SmPC carries both requirements verbatim.

Against that backdrop the absolute risk is low and product-dependent. A retrospective cohort study in Annals of Internal Medicine in 2022 reported adjusted anaphylaxis rates per 10,000 first administrations of 9.8 (95% CI 6.2–15.3) for iron dextran, 4.0 (2.5–6.6) for ferumoxytol, 1.5 (0.3–6.6) for ferric gluconate, 1.2 (0.6–2.5) for iron sucrose and 0.8 (0.3–2.6) for ferric carboxymaltose. Using iron sucrose as the reference, the adjusted odds ratio was 8.3 for iron dextran and 3.4 for ferumoxytol.

A separate phenomenon is routinely mistaken for allergy. The self-limiting flushing and truncal tightness that can appear minutes into an infusion, without hypotension, wheeze or urticaria, is a complement-mediated reaction rather than an IgE one; it typically settles when the infusion is paused and does not necessarily contraindicate future treatment. Reading it as anaphylaxis ends a course that did not need to end. Reading anaphylaxis as it, of course, is the far more dangerous error — which is precisely why the setting, not the product, is the safety measure.

Where the randomised evidence is strongest

Correcting a laboratory value is not the same as changing an outcome, and intravenous iron has been tested on hard endpoints in one population more than any other.

The 2023 focused update to the European Society of Cardiology heart failure guidelines gives intravenous iron a Class I, Level A recommendation in symptomatic patients with reduced or mildly reduced ejection fraction and iron deficiency, to relieve symptoms and improve quality of life, and a Class IIa, Level A recommendation for ferric carboxymaltose or ferric derisomaltose to reduce the risk of heart failure hospitalisation.

The individual trials are less tidy than the grading suggests. HEART-FID, published in the New England Journal of Medicine in 2023, found no apparent difference between ferric carboxymaltose and placebo on its hierarchical composite primary outcome. AFFIRM-AHF and IRONMAN reported their positive composite results through prespecified COVID-adjusted analyses. A pooled analysis in Nature Medicine in March 2025 found that intravenous iron significantly reduced the composite of recurrent heart failure hospitalisations and cardiovascular death, with the effect greatest in the first year and driven particularly by hospitalisations.

Read honestly, the gradient is the finding: strong and consistent for symptoms and quality of life, real but hospitalisation-weighted for events, and absent for survival. The guideline grading mirrors it exactly, which is rarer than it should be.

There is also a harm signal that deserves to sit beside the benefit. A systematic review of 154 randomised trials and 32,762 participants in JAMA Network Open in 2021 — corrected in 2022 — found an increased risk of infection with intravenous iron, a relative risk of 1.16 (95% CI 1.03–1.29), about sixteen additional infections per 1,000 people treated, alongside a reduced need for red-cell transfusion (RR 0.83, 0.76–0.89) and no difference in short- or long-term mortality. The authors flagged substantial inconsistency in how infection was defined, with 49 trials providing no a priori definition. The mechanistic rationale — a transient rise in non-transferrin-bound iron, which is usable by pathogens — is plausible rather than proven. It is a reason to have an indication, not a reason to refuse one.

Fatigue without anaemia: the contested indication

The commercial centre of gravity for iron infusions is not heart failure. It is tiredness in people whose haemoglobin is normal, and here the randomised record genuinely conflicts.

PREFER, published in PLoS One on 21 April 2014, randomised 294 fatigued, iron-deficient women with normal or borderline haemoglobin to a single 1,000 mg infusion of ferric carboxymaltose or saline. At day 56, 65.3% in the iron arm had improved by at least one point on the Piper Fatigue Scale against 52.7% on placebo (p = 0.03), and 33.3% against 16.4% achieved a 50% reduction (p < 0.001). The trial was single-blinded, and the authors noted that limitation themselves.

The ISUB trial, published in Scientific Reports in 2020, is the mirror image. It randomised 405 non-anaemic repeat blood donors with ferritin at or below 50 µg/L to 800 mg of ferric carboxymaltose or placebo, double-blinded. Mean self-rated fatigue at six to eight weeks was 3.9 ± 1.8 with iron and 4.0 ± 2.2 with placebo (p = 0.819), with no differences in psychological distress, sleep quality or general health.

An abridged Cochrane review in the Journal of Cachexia, Sarcopenia and Muscle in 2022 pooled 21 trials and 3,514 participants: peak oxygen consumption improved by 1.77 mL/kg/min (0.57–2.97), fatigue by a standardised mean difference of −0.30 (−0.52 to −0.09), ferritin by 245.52 µg/L and haemoglobin by 4.65 g/L, with no overall difference in quality of life, more mild adverse events (RR 1.77, 1.10–2.83) and certainty of evidence rated low to very low for most outcomes.

The two trials are not really contradictory once you read who was enrolled. PREFER selected women for fatigue and treated them unblinded to the infusion; ISUB enrolled donors who were not selected for symptoms at all, under full blinding. A small effect in symptomatic, genuinely depleted people, shrinking to nothing in people who were merely low on a blood test, is what both datasets together describe. Neither licence covers the indication, and the honest summary is that the benefit, where it exists, is modest and depends entirely on who is in the chair.

The ceiling nobody mentions

Every other molecule in this series has had a lower bound and a vague upper one. Iron has a measurable ceiling, and it is the part of the conversation that infusion marketing omits.

A multivariate genomic scan of healthspan, parental lifespan and longevity published in Nature Communications in 2020 implicated haem metabolism in human ageing, and its Mendelian randomisation analysis found evidence of a causal effect of serum iron on those outcomes — in the direction of higher iron status predicting a shorter healthy life. A companion Mendelian randomisation analysis in Clinical Nutrition the same year reached a consistent conclusion on genetically predicted iron status and life expectancy. Genetic instruments describe lifelong exposure rather than the effect of a single infusion, and that distinction should be kept; the signal is nonetheless the clearest upper-bound evidence any nutrient in this series has.

The chemistry is unambiguous. Iron that is not bound to transferrin catalyses the conversion of hydrogen peroxide into the hydroxyl radical, the most indiscriminately destructive species a cell encounters. The enzymes that keep that reaction from happening — catalase and glutathione peroxidase — exist precisely because loose iron and peroxide coexist in every aerobic cell. Ferroptosis, the iron-dependent form of cell death built on that chemistry, is now an active target in ageing research, though the therapeutic work remains preclinical.

None of this argues against treating deficiency. It argues against treating a number upwards for its own sake. "Topping up" is a coherent idea for a water-soluble vitamin that is excreted within hours; applied to iron, it describes the one intervention in this series where overshoot has a documented downside.

Who actually has the deficiency

Iron deficiency is genuinely common, and it is unevenly distributed in a way that matters for how infusions get sold.

A systematic review published in the Journal of Clinical Medicine on 4 August 2026 pooled eight cross-sectional studies and 26,412 participants from Saudi Arabia. Prevalence was consistently higher in women across every population: 34.2% of adolescent girls against 16.7% of boys, 51.1% to 67.4% of female university students against 0% to 4.7% of men, and 21.6% of community-dwelling adult women. One national study reported iron deficiency in 28.6% and iron-deficiency anaemia in 10.7%, with 94.1% of the anaemia cases female. Figures from the United Arab Emirates are sparser and come mostly from small self-reported surveys, so regional estimates should be read as indicative rather than precise — but the direction is not in doubt, and it points at exactly the population the regional infusion market advertises to.

The clinical rule does not change with the market: iron deficiency is a finding, not a diagnosis, and British Society of Gastroenterology guidance treats establishing its cause as part of the treatment rather than an optional extra. In an adult man or a postmenopausal woman, iron deficiency is a reason to look for blood loss. Correcting the number without that step treats the measurement and leaves the mechanism in place.

The overlap is the uncomfortable part. The demographic with the highest real prevalence of iron deficiency — women of reproductive age — is also the demographic most intensively marketed to by aesthetic and wellness infusion services. That is exactly why the diagnostic step is the dividing line between a licensed treatment and an unlicensed one, and why the licence puts it in writing.

Evidence, formulation and regulatory status, graded

Sorted by what is being claimed, for whom, and on what evidence, intravenous iron separates cleanly from the category it is sold alongside.

How to read an iron infusion offer

Four questions separate a prescription from a purchase.

First, what are my ferritin and transferrin saturation, and what is causing the deficiency? The licence requires the first half; good medicine requires the second. A result alone is not an indication, and a service that will infuse without a recent iron panel is operating outside the terms of the product it is using.

Second, which product, and what is the phosphate plan? After 1 September 2026 this is no longer a technicality. If the answer is ferric carboxymaltose, there should be a baseline phosphate in anyone with a risk factor, a stated plan for repeat courses within three months, and an explanation of which musculoskeletal symptoms to report. If the clinic cannot name the molecule it is infusing, that is the answer to the question.

Third, where is it being given, and by whom? Not in a hotel room, not at a desk. The EMA's 2013 position is still the standard: trained staff, full resuscitation facilities, observation for at least thirty minutes, and no test dose, because a test dose provides false reassurance rather than information.

Fourth, what happens afterwards? Ferritin measured in the weeks following an infusion reflects the infusion, not the stores — the pooled rise is around 245 µg/L — so a reassuring number at two weeks means very little. A sensible re-test interval, a plan for the underlying cause, and a decision rule for whether a second course is needed are what distinguish treatment from a transaction.

Iron is the exception that proves the series' rule. The route earns its claim here because a real delivery problem exists, and the moment that is true, the product stops being a wellness item and becomes a medicine with a licence, a boxed warning and an open safety review attached to it. That is the trade, and it is the correct one. EFBA supplies no iron product and makes no claim in this field; what the two cases share is a method. A concept such as IVIXIR MetilPlus, built on B-group vitamins, or IVIXIR Sodium Ascorbate 7500 MD is a defined set of molecules at stated concentrations — not a treatment for iron deficiency, anaemia or any other condition, and the series has said the same about B12 and folate and about cobalamin and folate individually. What can be specified can be assessed; what has been assessed by a regulator should be used the way the regulator assessed it.